Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.
Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.
Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.
Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.
Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5 .